Guobang Pharma Ltd.

SHSE:605507 Voorraadrapport

Marktkapitalisatie: CN¥10.8b

Guobang Pharma Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Guobang Pharma has been growing earnings at an average annual rate of 2.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 8.7% per year. Guobang Pharma's return on equity is 8.9%, and it has net margins of 12.3%.

Belangrijke informatie

2.4%

Groei van de winst

-0.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie10.9%
Inkomstengroei8.7%
Rendement op eigen vermogen8.9%
Nettomarge12.3%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)

Aug 26
Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)

These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively

Jul 24
These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively

Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially

May 21
Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially

Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)

Apr 18
Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)

We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt

Mar 25
We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt

Opbrengsten en kosten

Hoe Guobang Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

SHSE:605507 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 245,714702347188
30 Jun 245,432660367186
31 Mar 245,278617361181
31 Dec 235,349612358191
30 Sep 235,661689401225
30 Jun 235,827783383208
31 Mar 235,955915358213
31 Dec 225,721921352198
30 Sep 225,405906312184
30 Jun 224,966823302173
31 Mar 224,539721313154
31 Dec 214,505706299155
30 Sep 214,273694277146
30 Jun 214,317741259143
31 Mar 214,449834316170
31 Dec 204,206810241137
31 Dec 193,802315243124
31 Dec 183,279211216103
31 Dec 172,90517820295

Kwaliteitswinsten: 605507 has high quality earnings.

Groeiende winstmarge: 605507's current net profit margins (12.3%) are higher than last year (12.2%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: 605507's earnings have grown by 2.4% per year over the past 5 years.

Versnelling van de groei: 605507's earnings growth over the past year (1.9%) is below its 5-year average (2.4% per year).

Winst versus industrie: 605507 earnings growth over the past year (1.9%) exceeded the Pharmaceuticals industry -1.2%.


Rendement op eigen vermogen

Hoge ROE: 605507's Return on Equity (8.9%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden